You are here: Home » News-CM » Equities » Hot Pursuit
Business Standard

Lupin gains after receiving USFDA approval for Armodafinil tablets

Capital Market 

rose 0.85% to Rs 1,530 at 9:52 on after the company said it received a final approval from the US drug regulator to market a generic version of Cephalon Inc's Nuvigil tablets.

The announcement was made after market hours yesterday, 29 November 2016.

Meanwhile, the Sensex was up 67.23 points, or 0.25%, to 26,461.24.

On BSE, so far 25,000 shares were traded in the counter, compared with average daily volume of 99,927 shares in the past one quarter. The stock hit a high of Rs 1,545.55 and a low of Rs 1,526.90 so far during the day. The stock hit a 52-week high of Rs 1,911.55 on 9 February 2016. The stock hit a 52-week low of Rs 1,294.05 on 29 March 2016. The stock had outperformed the market over the past 30 days till 29 November 2016, falling 0.06% compared with the 5.50% decline in the Sensex. The scrip had also outperformed the market in past one quarter, rising 2.25% as against Sensex's 7.23% decline.

The large-cap company has equity capital of Rs 90.27 crore. Face value per share is Rs 2.

announced that its US subsidiary Pharmaceuticals Inc (LPI) has received final approval from the United States Food and Drug Administration (USFDA) to market Armodafinil tablets 50mg, 150mg, 200mg and 250mg. LPI shall commence promoting the product in the US shortly. Lupin's Armodafinil tablets are the AB rated generic equivalents of Cephalon, Inc's Nuvigil tablets. Armodafinil tablets are indicated to improve wakefulness in adult patients with excessive sleepiness associated with obstructive sleep apnea (OSA), narcolepsy or shift work disorder (SWD). Nuvigil tablets had annual US sales of $515.6 million as per IMS MAT September 2016 data.

Lupin's consolidated net profit jumped 57.8% to Rs 662.19 crore on 31.9% rise in net sales to Rs 4211.18 crore in Q2 September 2016 over Q2 September 2015.

Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) globally. The company is a significant player in the cardiovascular, diabetology, asthma, pediatric, central nervous system (CNS), GI, Anti-Infective and NSAID space and holds global leadership position in the Anti-TB segment.

Powered by Capital Market - Live News

(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

First Published: Wed, November 30 2016. 09:47 IST